Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents.
Moulopoulos
L A
LA
Dimopoulos
M A
MA
Christoulas
D
D
Kastritis
E
E
Anagnostou
D
D
Koureas
A
A
Roussou
M
M
Gavriatopoulou
M
M
Migkou
M
M
Iakovaki
M
M
Gkotzamanidou
M
M
Tasidou
A
A
Terpos
E
E
D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D015415:Biomarkers / Q000032:analysis; D001847:Bone Diseases / Q000473:pathology*; D001853:Bone Marrow / Q000098:blood supply* / Q000473:pathology; D016723:Bone Remodeling; D016207:Cytokines / Q000378:metabolism; D038524:Diffusion Magnetic Resonance Imaging; D005260:Female; D006801:Humans; D008297:Male; D009101:Multiple Myeloma / Q000098:blood supply* / Q000188:drug therapy / Q000473:pathology*; D009367:Neoplasm Staging; D009389:Neovascularization, Pathologic / Q000175:diagnosis*; D011379:Prognosis; D015996:Survival Rate
D000970:Antineoplastic Agents; D015415:Biomarkers; D016207:Cytokines